Gilead Sciences (GILD) EBIT Margin (QoQ) (2009 - 2026)
Powered by 
Analysis
Gilead Sciences (GILD) EBIT Margin (QoQ) (2009 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 207.17 Bn | 193.18 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.52 Bn | 176.34 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 131.47 Bn | 123.62 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.73 Bn | 73.74 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.16 Bn | 55.98 Bn | 1.37 Bn |
| 6 | Moderna | 53.28 Bn | 48.14 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.06 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.65 Bn | 30.37 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.30 Bn | 29.30 Bn | 1.16 Mn |
| 10 | Insmed | 27.68 Bn | 26.52 Bn | 358.27 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -17,036.00 |
| Mar 31, 2026 | 1,212.00 |
| Dec 31, 2025 | -1,779.00 |
| Sep 30, 2025 | 789.00 |
| Jun 30, 2025 | 138.00 |
| Mar 31, 2025 | 116.00 |
| Dec 31, 2024 | 2,063.00 |
| Sep 30, 2024 | -2,625.00 |
| Jun 30, 2024 | 10,266.00 |
| Mar 31, 2024 | -8,730.00 |
| Dec 31, 2023 | -1,454.00 |
| Sep 30, 2023 | 1,197.00 |
| Jun 30, 2023 | -161.00 |
| Mar 31, 2023 | -384.00 |
| Dec 31, 2022 | -961.00 |
| Sep 30, 2022 | 787.00 |
| Jun 30, 2022 | 2,942.00 |
| Mar 31, 2022 | -999.00 |
| Dec 31, 2021 | -3,880.00 |
| Sep 30, 2021 | 1,565.00 |